For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Former public offices
Economist, Financial Sector Policy Branch, Department of Finance (1998–2000)
Research Associate: Task Force on the Future of the Canadian Financial Services Sector, Financial Sector Policy Branch, Department of Finance (1997–1997)
Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to regulatory burden, including “cutting red tape”.
Inter-provincial harmonization and trade barriers as it relates to insurance products.
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to regulatory burden, including “cutting red tape”.
Financing infrastructure projects, as it relates to investments by insurers
Greg Orencsak · Deputy Minister, Health Canada (HC)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
Maggie Chi · Parliamentary Secretary to Minister of Health, Health Canada (HC)
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.Read more
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to regulatory burden, including “cutting red tape”.
Financing infrastructure projects, as it relates to investments by insurers
Financing infrastructure projects, as it relates to investments by insurersRead more
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.
Discussions related to regulatory burden, including “cutting red tape”.
Discussions related to regulatory burden, including “cutting red tape”.Read more
Financing infrastructure projects, as it relates to investments by insurers
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.
Wayne Long · Secretary of State (Canada Revenue Agency and Financial Institutions) (Secretary of State), Finance Canada (FIN)
Kevin Collins · Chief of Staff, Finance Canada (FIN)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Financing infrastructure projects, as it relates to investments by insurers
Discussions related to regulatory burden, including “cutting red tape”.
Kevin Collins · Chief of Staff, Finance Canada (FIN)
Joshua Mbandi · Director of Policy, Finance Canada (FIN)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to regulatory burden, including “cutting red tape”.
Promotion of a broader range of investments by insurance companies (e.g., farmland, timberland, fintechs)
Financing infrastructure projects, as it relates to investments by insurers
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Financing infrastructure projects, as it relates to investments by insurers
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB)Read more
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB)
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB)Read more
Discussions related to regulatory burden, including “cutting red tape”.
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
Greg Orencsak · Deputy Minister, Health Canada (HC)
Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.Read more
Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB)
Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.